LONDON, July 20, 2017 /PRNewswire/ --
Colorado was the first U.S. state to set up a booming legal marijuana industry a few years ago, inspiring other states to follow suit. Bit by bit, the dominoes are starting to fall and marijuana is slowly becoming more available across the country.
However, the federal government is once again hostile to marijuana - with Attorney General Jeff Sessions a particularly fierce opponent of legalization - raising questions about what comes next. Keeping a close eye on operations include: Cara Therapeutics, Inc. (NASDAQ: CARA), Cronos Group Inc. (TSX-V: MJN.V), The Scotts Miracle-Gro Company (NYSE: SMG), 22nd Century Group, Inc. (NYSE: XXII), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
But America's northern neighbor does not have that problem. The Canadian government is moving quickly to legalize marijuana and, unlike the patchwork state-by-state approach unfolding in the U.S., Canada is set to make it legal nationwide by this time next year.
That has kicked off speculation of a green gold rush in Canada, a market that Deloitte estimates could be worth more than $22 billion annually.
It is an investor's dream: a market where there is huge pent up demand not currently being met, and federal legislation slated to open the flood gates. Even better, because marijuana suppliers must register and receive approval from the federal government to sell products, there are serious barriers to entry. This presents a massive case of "first-mover advantage" - the companies that get approved first will cash in on the legal marijuana bonanza.
One company in particular is poised to capture a sizable share of the market. Invictus MD (IMH.V; IVITF), a legal medical marijuana provider, is ready to hit the ground running when federal legalization passes. Here are five reasons why Invictus is a crucial company for investors to keep an eye on.
1. First-mover advantage. There are a little more than 50 licensed producers of marijuana, but Health Canada, the federal regulator, recently decided to accelerate the licensing process, recognizing that there might not be enough supply when legalization comes into effect on July 1, 2018. Invictus MD is one of these companies that has 2 of the 50 licenses in 2 major provinces, perfectly positioned to capitalize on what is largely a captive market. There are more than 400 other companies in line awaiting their licenses, but Invictus is ready to go. And there is growing speculation that suppliers will struggle to meet market demand in 2018.
2. Invictus is the first integrated marijuana-dividend stock. Invictus is the first marijuana supplier to pay a dividend to shareholders, dishing out $1 million last December. Invictus was able to do this through a series of prudent acquisitions, including upstream cultivators as well as fertilizer producers.
Last December, Invictus acquired a 33.33 percent stake in AB Laboratories Inc., a licensed producer of medical marijuana in Ontario. It also has a 33.33 percent stake in AB Ventures, which will expand Invictus' marijuana cultivation capacity based on the 100 acres AB Ventures owns. In April, it acquired a 100 percent stake in Acreage Pharms, another licensed producer in Alberta. "With the Company's acquisition of 100 percent of Licensed Producer Acreage Pharms in Alberta, we now have 250 acres of cultivation space that stretches from Alberta to Ontario," Dan Kriznic, executive chairman of Invictus, said in an April statement.
In fact, Invictus MD (IMH.V; IVITF) has stitched together assets that make it an integrated marijuana supplier, and will benefit from selling marijuana, but also from the growth of the sector as a whole. Through the sale of fertilizers, Invictus will profit even from its competitors. As was the case with the gold rush, some of the biggest winners were the sellers of picks and shovels rather than just the explorers who found gold.
3. Market is huge. The Canadian medical marijuana market alone is worth $400 million, and growing rapidly. But that will be a small fraction of the recreational market, which will become legal in a year.
There are around 150,000 medical marijuana users, but some see the recreational market exploding to 4 million users in the first few years of legalization, with sales exceeding $8 billion annually. Deloitte says the economic impact could reach $22.6 billion - a figure larger than the wine, beer and spirits market.
When compared to the $6.7 billion size of the U.S. marijuana market, Canada's legal marijuana market could exceed that of its much larger southern neighbor.
4. Medical marijuana companies are already exploding on the prospect of legalization. Legalization is sweeping the continent, opening up lucrative opportunities for companies that have existed for a long time by servicing the medical marijuana market. As governments relent on legalization, the valuation of medical marijuana stocks have skyrocketed. Here are the gains from 2016 for the top medical marijuana producers:
• AXIM Biotechnologies: exploded 1,720 percent
• Corbus Pharmaceuticals was up 431 percent
• Aphria grew 381 percent
• Aurora Cannabis was up 299 percent
• Canopy Growth Corp. up 259 percent
• Medical Marijuana up 254 percent
• GW Pharmaceuticals was up 64 percent
But the marijuana bonanza is set to continue with the recent launch of the first cannabis-based exchange-traded fund (ETF), called the Horizons Medical Marijuana Life Sciences ETF. The new ETF will spark a wave of investment into marijuana stocks. Invictus is included in the ETF, along with about two dozen other marijuana suppliers.
5. Top-notch management. Invictus MD is headed up by a great management team, with experience growing small companies. They have multiple strains of marijuana, ranging from pain management to cancer, epilepsy and anxiety. And, of course, the recreational sector is a massive gold mine-in- waiting. But while dozens and even hundreds of companies are rushing to build their marijuana supply chains from scratch, Invictus MD (IMH.V; IVITF),management has been carefully putting together the seeds of a hugely profitable marijuana supplier for years. Dan Kriznic, executive chairman and founder, has a track record of transforming small companies in a variety of sectors to multi-million-dollar enterprises.
The legalization of marijuana in the U.S. sparked a proliferation of suppliers and a wave of money from investors looking to cash in on the billion-dollar market that was created virtually overnight. But the Canadian market is almost unknown to many big investors, which means there is huge untapped potential for those in the know. There is no shortage of catalysts on the near-term horizon, and full legalization in Canada is a year away. Invictus is one of the few candidates set to profit from this green gold rush.
Cara Therapeutics Inc (NASDAQ: CARA) is a clinical-stage bio pharmaceutical company. The Company is focused on developing and commercializing pharmaceutics designed to alleviate pain. Now that 28 states have passed bills regarding medical and recreational marijuana use and more and more people are turning to medical marijuana for its painkilling abilities, we see good long-term upside for this stock.
The Cronos Group. (TSX-V: MJN.V): Cronos is one of Canada's most active investment firms in the medicinal marijuana sector. The company invests mainly in licensed cannabis growers and is one of the holdings in the brand Marijuana Life Sciences ETF. Cronos fell back last month, but looks like a real value stock at this point in time
Scotts Miracle-Gro Co (NYSE: SMG): This household name has its sights clearly set on the marijuana boom, expanding into emerging areas such as hydrophonics in an attempt to stay ahead of the curve in a competitive industry. It has rebounded from its recent lows and is looking promising for shareholders.
22nd Century Group, Inc. (NYSE: XXII): A biotechnology company that that develops, markets and licenses genetically modified cannabis, marijuana and hemp. As the green rush picks up pace, there will undoubtedly be growth in this market and large gains for those who find themselves at the front. The tobacco products of 22nd Century Group, Inc provides the diversification that many investors require when entering a new market.
Corbus Pharmaceuticals (NASDAQ: CRBP): For investors looking for a stock with more risk but more upside, Corbus Pharmaceutcals looks promising. Currently sitting near a six month low, the company is looking for its clinical trials to come good, allowing it to corner some of the biggest markets in the medical marijuana industry.
Legal Disclaimer/Disclosure from OilPrice.com: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Oilprice.com only and are subject to change without notice. Oilprice.com assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. All content contained herein is subject to the terms and conditions set forth in the original article posted on Oilprice.com and subject to the terms and conditions therein.
DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611